Corcept Therapeutics (CORT) has submitted a new drug application to the FDA for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics presents results from relacorilant study
- Corcept Therapeutics says CATALYST trial met primary endpoint
- Corcept says DAZALS study did not meet primary endpoint
- Corcept Therapeutics price target raised to $73.50 from $72 at Ladenburg
- Corcept Therapeutics Reports Strong Q3 Results and Positive Trial Outcomes